GlassScriptPhysician profile
Nicholas Alan Beckmann
NPI 1891114260
$151,179.13
in general payments reported to CMS, 2019-2025
18 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $413 · 2021: $1,092 · 2022: $1,565 · 2023: $24K · 2024: $38K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $114K · Honoraria: $20K · Travel and Lodging: $8,563 · Food and Beverage: $5,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $114,063.75 |
| Honoraria | $20,000.00 |
| Travel and Lodging | $8,562.77 |
| Food and Beverage | $5,325.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $149,433.26 | 2020-2025 | Inspire |
| Smith+Nephew, INC. | $321.68 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $278.39 | 2019-2025 | Tezspire |
| Medtronic, INC. | $264.62 | 2022-2025 | Propel |
| Aerin Medical INC. | $187.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $183.07 | 2021-2025 | Nucala |
| Genzyme Corporation | $111.92 | 2022-2025 | |
| Stryker Corporation | $74.12 | 2020-2022 | |
| Galderma Laboratories, L.P. | $73.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.28 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $34.18 | 2025 | Zepbound |
| Neurent Medical Limited | $28.46 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Amgen INC. | $28.07 | 2025 | Tezspire |
| Itamar Medical INC | $25.36 | 2025 | Watchpatone |
| Optinose US, INC. | $22.91 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2023 | Takhzyro |
| Steris Corporation | $19.31 | 2025 | |
| Ambu INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Beckmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.